Overview
Retatrutide is a triple receptor agonist — the first research peptide to simultaneously activate GLP-1, GIP, and glucagon receptors. Developed as a next-generation metabolic compound, it represents the cutting edge of incretin-based research and has generated significant interest for its outsized metabolic effects compared to single- and dual-agonist compounds.
Early phase II data has made retatrutide the fastest-growing research peptide category in 2025–2026, with researchers citing its unique triple-receptor profile as enabling study designs not possible with semaglutide or tirzepatide.
Mechanism of Action: Triple Agonism
Retatrutide activates three distinct receptor pathways simultaneously:
- GLP-1R agonism — insulin secretion stimulation, glucagon suppression, gastric emptying delay, central appetite reduction (same pathway as semaglutide)
- GIPR agonism — synergistic insulin enhancement, adipocyte metabolism regulation (same as tirzepatide's second receptor)
- Glucagon receptor agonism — the critical differentiator. Glucagon receptor activation in the liver increases hepatic fat oxidation and energy expenditure, creating a metabolic effect profile distinct from all prior incretin compounds
The glucagon receptor component is counterintuitive — glucagon is normally associated with raising blood glucose — but at the doses used in research models, the hepatic fat oxidation effect dominates, and the GLP-1 component mitigates any glycemic impact. The result is a compound that combines aggressive fat mobilization with robust appetite suppression.
Key Research Data
Phase II data published in the New England Journal of Medicine (2023) established retatrutide's research benchmark figures:
- 24.2% mean body weight reduction at 48 weeks (highest dose cohort) — exceeding both semaglutide (~15%) and tirzepatide (~21%) in head-to-head timeline comparisons
- Significant reductions in liver fat fraction — making retatrutide particularly relevant for hepatic metabolism research
- Dose-dependent response observed across 1mg, 4mg, 8mg, and 12mg weekly cohorts
- Favorable lipid profile changes: decreased triglycerides, LDL, and VLDL across all dose groups
Pharmacokinetics
| Parameter | Value |
|---|---|
| Half-life | ~6 days |
| Time to steady state | 4–5 weeks |
| Dosing interval (research) | Weekly |
| Receptor targets | GLP-1R + GIPR + GcgR |
| Molecular weight | ~4,969 Da |
Why Retatrutide Matters for Researchers
Retatrutide enables research designs that were previously impossible: isolating the glucagon receptor's contribution to hepatic fat metabolism independent of its glycemic effects, studying triple-pathway receptor synergy, and benchmarking the ceiling of incretin-driven metabolic response. It also provides the strongest available reference compound for body composition research, offering a higher-magnitude response signal for dose-response studies.
For researchers building protocols comparing next-generation compounds, retatrutide is the current upper benchmark in the incretin agonist category.
All products sold by My Freedom Peptides are for research use only. Not intended for human consumption, medical treatment, or diagnostic use.
The Freedom Files
Don’t Miss the Next Article
Join our email list for weekly research insights, new product drops, and exclusive deals.
Join the ListFor research use only. Not intended for human consumption. These statements have not been evaluated by the Food and Drug Administration.
Frequently Asked Questions
What is Retatrutide?
Retatrutide is a triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. It represents the next generation of metabolic research peptides beyond dual agonists like Tirzepatide.
What makes Retatrutide unique?
Retatrutide is the only research peptide that activates three separate metabolic receptor pathways — GLP-1R, GIPR, and GcgR. The glucagon receptor component adds thermogenic and hepatic effects not seen in dual agonists.
What has Retatrutide research documented?
Phase II trials have documented weight reductions exceeding 24% at the highest dose over 48 weeks — the largest reduction recorded in any GLP-class peptide study to date. Research is ongoing across multiple endpoints.
Does My Freedom Peptides Retatrutide have endotoxin testing?
Yes. Our Retatrutide (3G-RT) has both HPLC purity verification (99.96%) and endotoxin testing completed via LAL assay using USP <85> standards. Both endotoxin replicates passed at ≤0.05 EU/mL.
How should Retatrutide be reconstituted?
Reconstitute with bacteriostatic water. Use our Peptide Reconstitution Calculator on the site to determine exact draw volumes for your protocol. Store reconstituted peptide at 2–8°C and use within 28 days.